The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

Semaglutide 2.4 mg injection (Wegovy, Novo Nordisk) is now indicated for this patient population, along with a reduced calorie diet and increased physical activity, according to the manufacturer.

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH, bringing us closer to care that meets the needs of people living with this disease,” Arun Sanyal, MD, director of the Stravitz-Sanyal Institute for Liver Dis

See Full Page